Understanding how cancer cells repair DNA to survive treatment
Official title: Investigating the Role of Mutagenic DNA Repair during the Persistence of Cancer Cells
Funded at Sloan-Kettering Inst Can Research · NIH-11071199 · Data updated 2026-11-12
This study looks at how cancer cells fix their DNA to survive treatment, especially in patients with BRCA1/2 mutations, and aims to find new ways to make cancer therapies work better for everyone.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | March 1, 2025 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $80,702 |
| NIH project number | 1F32CA298730-01 |
| Project ID | NIH-11071199 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include patients with BRCA1/2 mutations or those experiencing acquired drug resistance in their cancer treatment.
✕Less likely to help
Patients with cancers that do not involve BRCA1/2 mutations or those not undergoing treatment with DNA-damaging agents may not benefit from this research.
What this research studies
This research investigates how cancer cells use different DNA repair mechanisms to survive the effects of anti-cancer drugs. It focuses on the role of error-prone repair pathways that may lead to drug resistance, particularly in cancers with BRCA1/2 mutations. By studying how these cells adapt and persist under treatment stress, the research aims to uncover new strategies to overcome resistance and improve cancer therapies. Patients may benefit from insights that could lead to more effective treatments.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer treatments that prevent drug resistance and enhance patient outcomes.
How similar studies have gone: Previous research has shown that understanding DNA repair mechanisms can lead to breakthroughs in cancer treatment, indicating that this approach has potential for success.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Kelley, Megan Elizabeth — Sloan-Kettering Inst Can Research
- Study coordinator: Kelley, Megan Elizabeth
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.